Sensus Healthcare INVESTOR OVERVIEW
25Pages

Sensus Healthcare INVESTOR OVERVIEW

Safe Harbor Statement Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forwardlooking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. By their nature,...

Large U.S. market for Superficial Radiation Therapy (SRT) with OUS and pipeline opportunities ○ SRT systems allow practitioners an ROI in as little as 6-9 months, with 50+% increased reimbursement for course of treatment to improve ROI (01/02/2021) Recurring revenue opportunity with Sentinel™ − a powerful I.T. platform that provides Sensus’ customers with Asset Management capabilities as well as HIPAA compliant Patient Data collection Received a five-year license renewal for the SRT-100™ from the Chinese Health Authority Added TransDermal Infusion System ™ distribution for needle-free...

Core Technology - SRT SRT-100+™ SRT-100 Vision™ ● Low-energy Photon Radiotherapy ○ ○ ○ Scalable platform – new future indications, such as psoriasis ○ ○ 100% of the energy is focused directly on surface of skin using customized proprietary applicators Penetrates no deeper than 5mm below skin’s surface Covered by IP portfolio Being studied at Holy Name Hospital in Teaneck, NJ for treatment of hospitalized COVID-19 pneumonia patients Installed at Colorado State U Veterinary Hospital for animal cancer treatment Sentinel multi-featured, state-of-the-art cloud platform S

For Non-Melanoma Skin Cancer (NMSC)

American Academy of Dermatology-RBC Consultants “1 in 5 Americans will develop skin cancer in their lifetime”

Mohs Surgery Mohs surgery can last for several hours, with the patient sitting in a chair with only a local anesthetic Page 7

SRT: Superior Clinical Outcomes

What are Keloids? ▪ A keloid is an area of irregular fibrous tissue formed at the site of a scar or injury* *Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225895/ Journal of Family Practice (May 2013); Keloids: Which treatment is best for your patient? Surgery and other current treatment methods are not a permanent solution Recurrence rates of keloids are up to 80% Expensive treatments are usually paid out-of-pocket by the patient Insurance covers treatment only if combined with SRT Sensus is the only FDA cleared system to treat keloids

Clinical Studies Skin Cancer: ● Clinical multi-center study in 2019 of 776 lesions, 5-year retrospective study – 98.9% cure rate ● Clinical study of 151 lesions on lower extremities in 2018, 97.35% cure rate and 5-year success rate of 97% ● Cognetta et al (2012) retrospective analysis on 1,715 confirmed primary cutaneous basal cell carcinoma (“BCC”) and squamous cell carcinoma (“SCC”) treated with SRT between 2000 and 2010; 5-year recurrence rate 5% Keloids: ● Clinical study in 2018 on keloid surgery followed with SRT for 297 lesions had 97% success rate ● Dr. Michael Jones; Long term...

The SRT-100 Vision Unique, image-guided therapy: “See & treat” World’s first designed to: ○ Track disease progression ○ Plan treatment ○ Guide therapy ○ Administer radiation ○ Evaluate treatment ○ Ultrasound capabilities ○ 1M+ ultrasound

Full Array of Proprietary Applicators

TransDermal Infusion™

TransDermal Infusion No Needles FDA-Cleared Alternative to Injections Applications ● ● ● ● ● ● ● ● ● ● ● ● ● ● Skin Rejuvenation Hair Restoration Hyperpigmentation PRP Regenerative Modalities Hyaluronic Acid Growth Factor and Peptides Vitamin C Pre- and post-Micro-Needling Treatments Hyperhidrosis – ○ Botulinum Toxin Administration Anesthetic prior to an invasive procedure Steroid Applications Sexual Wellness (P-Shot) A

SMART LASERS powered by SENTINEL ▪ ▪ ▪ The very 1st in the world – Smart Lasers, powered by SENTINEL Lasers with a Brain providing 2-way communication Asset Management and Patient Data Storage on the Cloud

Sentinel IT Solution Introducing our state-of-the-art cloud platform. Sentinel is optional on all Sensus SRT and Laser equipment. Data and cloud storage Remote diagnostics HIPAA compliant billing iOS compatible

One-time sale of capital equipment with annual service contract ○ Sentinel™ software provides capability for recurring/shared revenue programs Recurring revenue from service contracts – 50% of installed base under service contracts and growing (80%+ new installs are getting service contracts) Recurring revenue from SLAS – Laser Rental Program Distribution deals to add product to sales bag Investing in sales and marketing Investing in direct-to-consumer programs in conjunction with physicians Raising awareness for SRT treatment for keloids Goal is to continue profitability for 2022 and...

COVID-19 Impact & Reopening Plan The lights went out as the country shut down in March 2020 to combat COVID-19 ● ● ● As a result, the momentum Sensus experienced in 2019 especially in 4Q19 abruptly halted Sensus used the shutdown to keep in front of its customers, providing PPE, and sponsoring Zoom seminars for physicians to help them navigate the new rules for their practices SRT came to forefront in the armamentarium for non-melanoma skin cancer, especially in the COVID-19 environment, with increased utilization − even by Mohs surgeons The lights are slowly and cautiously coming on now,...

Management Team Joseph C. Sardano, Founder, Chairman & CEO ▪ Elscint Medical Imaging – VP driving Sales & Mktg, led to joint acquisition between GE & Picker Medical (Philips) Imaging totaling approximately $650M. GE Healthcare – GSM, Functional Imaging (Positron Emission Tomography) imaging group, capturing #1 market share, reached sales of $320 million within the first 24 months. CTI Molecular Imaging/Siemens Medical Imaging – SVP, Molecular Imaging. Built top caliber team; captured 35% mkt share in one year. Accelerated put/call option w/ Siemens resulting in $2.2 bln acquisition Michael...